Alle Storys
Folgen
Keine Story von Intercell AG mehr verpassen.

Intercell AG

EANS-Adhoc: Intercell acquires antibody technology platform to further exploit its capabilities to combat infectious diseases

  ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide
  distribution. The issuer is solely responsible for the content of this
  announcement.
Research & Development
06.05.2010
Vienna (Austria), May 6, 2010 - Intercell AG (VSE: ICLL) today 
announced that it has signed an agreement with Cytos Biotechnology 
Ltd. to acquire Cytos' platform technology for monoclonal antibody 
discovery. The technology is based on expression cloning of 
monoclonal antibodies from human B-cells and enables the 
identification of anti-infective antibodies to prevent and treat 
infectious diseases.
Under the agreed terms Intercell will pay EUR 15 million to Cytos. 
Intercell will own certain unpartnered monoclonal antibody assets, 
including promising pre-clinical anti-infective antibody candidates 
discovered by Cytos. The key scientists, who have very successfully 
developed the technology at Cytos, will be employed by Intercell. The
antibody technology complements Intercell's technology platforms and 
opens novel medically and commercially relevant applications for 
Intercell's Antigen Identification Program (AIP®). The AIP® has 
delivered promising vaccine candidates against Staphylococcus aureus 
(Phase II/III) and Pneumococcus (Phase I) infections, among others, 
and has also been the basis for partnerships in the antibody field 
with Merck & Co. and Kyowa Hakko Kirin in these indications, 
respectively.
In its future antibody discovery activities Intercell will focus on 
medically and commercially attractive AIP® derived disease targets 
including Group B Streptococcus and bacteria involved in hospital 
acquired infections.
"Cytos' outstanding antibody technology complements our innovative 
R&D technology platform and enables pipeline progression within our 
existing portfolio", stated Gerd Zettlmeissl, Chief Executive Officer
of Intercell.
Wolfgang Renner, CEO of Cytos, commented: "Intercell, as a leading 
anti-infective company, is ideally positioned through its Antigen 
Identification Program (AIP®), to capture the full value of our 
monoclonal antibody discovery platform. We are very glad that our 
technology will support Intercell in discovering important new 
monoclonal antibodies to combat infectious diseases."
Monoclonal antibodies form one of the fastest growing segments of the
pharmaceutical industry. The global monoclonal antibodies market was 
valued at USD 27.4bn in 2008, indicating a Compound Annual Growth 
Rate (CAGR) of almost 30% between 2000 and 2008.1
"Antibodies can be extremely effective for the prevention and 
treatment of infectious diseases. For example, the increasing rate of
antibiotic resistance among certain types of nosocomial pathogens 
makes it extremely difficult to control hospital acquired infectious 
diseases in critical situations. Anti-infective antibodies, well 
known in the medical arena before the advent of antibiotic 
treatments, have experienced a comeback and monoclonal antibody 
products are expected to contribute to the control of severe 
infections that otherwise might be untreatable in the future", 
explained Eszter Nagy, Senior Vice President Research at Intercell.
1 http://www.marketresearch.com/product/display.asp?productid=2515126
end of announcement                               euro adhoc

Further inquiry note:

Intercell AG
Lucia Malfent
Vice President, Global Head Corporate Communications
Tel. +43 1 20620-1303
lmalfent@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Index: ATX Prime, ATX
Börsen: Wien / official market

Weitere Storys: Intercell AG
Weitere Storys: Intercell AG